<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792024</url>
  </required_header>
  <id_info>
    <org_study_id>12-1841</org_study_id>
    <secondary_id>NCI-2013-00404</secondary_id>
    <secondary_id>R21CA173751</secondary_id>
    <nct_id>NCT01792024</nct_id>
  </id_info>
  <brief_title>MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Phase II Evaluation of MR-Guided Laser Induced Interstitial Thermal Therapy (LITT) for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well magnetic resonance (MR)-guided laser interstitial
      thermal therapy works in treating patients with prostate cancer. Laser therapy uses intense,
      narrow beams of light to cut and destroy tissue and may help treat prostate cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the oncologic efficacy of laster interstitial thermal therapy (LITT) with
      primary endpoint of undetectable cancer on magnetic resonance imaging (MRI)-guided biopsy of
      treatment zone at 3 months following treatment.

      SECONDARY OBJECTIVES:

      I. To evaluate oncologic efficacy at 12 months following treatment based on biopsy of the
      treatment zone.

      II. To determine treatment-related safety and toxicity. III. To longitudinally assess urinary
      and sexual function in the year following treatment.

      OUTLINE:

      Patients undergo MR-guided LITT.

      After completion of study treatment, patients are followed up at 1, 3, and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2013</start_date>
  <completion_date type="Actual">September 16, 2015</completion_date>
  <primary_completion_date type="Actual">September 16, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Undetectable Cancer on MRI-guided Biopsy of Ablation Zone Following Treatment</measure>
    <time_frame>At 3 months after ablation</time_frame>
    <description>The primary study end point was the number of patients with no cancer on MRI guided biopsy of the ablation zone at 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With Biopsy Cancer of the Treatment Zone</measure>
    <time_frame>At 12 months</time_frame>
    <description>A systematic 12-core biopsy was performed at 1 year and the number of patients with biopsy cancer was counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total Number of Patients With Any Adverse Events Related to the Treatment</measure>
    <time_frame>1,3, and 12 month after treatment and up to 12 months</time_frame>
    <description>Treatment-related toxicity measured by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in Terms of Urinary and Sexual Function in the Year Following Treatment Assessed Using the International Prostate Symptom Score (IPSS)</measure>
    <time_frame>At 1,3 and 12 months</time_frame>
    <description>International Prostate Symptom Score (IPSS) measures urinary symptoms and continence and it ranged 0 to 35. Lower values are considered better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in Terms of Urinary and Sexual Function in the Year Following Treatment Assessed Using Sexual Health Inventory in Men (SHIM)</measure>
    <time_frame>At 1,3 and 12 months</time_frame>
    <description>Sexual Health Inventory Score in Men (SHIM) measures sexual health and erectile function and it ranged 1 to 25. Lower values are considered better outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Stage I Prostate Cancer</condition>
  <condition>Stage II Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (LITT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo Magnetic Resonance imaging (MR) guided laser thermal therapy with Visualase Thermal Therapy device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Visualase Thermal Therapy</intervention_name>
    <description>MR guided laser ablation of prostate cancer</description>
    <arm_group_label>Treatment (LITT)</arm_group_label>
    <other_name>laser interstitial thermal therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Undergo MR-guided LITT</description>
    <arm_group_label>Treatment (LITT)</arm_group_label>
    <other_name>MRI</other_name>
    <other_name>NMR imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical characteristics:

               -  Stage T1c or T2a

               -  Prostate-specific antigen (PSA) &lt; 15 ng/ml or PSA density (PSA divided by
                  prostate volume in cubic centimeters) &lt; 0.15 ng/ml^3

          -  No evidence of metastatic disease based on National Comprehensive Cancer Network
             (NCCN) guidelines:

               -  Bone scan if PSA &gt; 20 ng/ml and clinical stage T1c

               -  Bone scan if PSA &gt; 10 ng/ml and clinical stage T2

          -  Biopsy requirements:

               -  Gleason score 7 or less

               -  25% or fewer biopsies with cancer

               -  At least 12 biopsy cores of the prostate

               -  Within 12 months of treatment

          -  Imaging requirements:

               -  Up to 2 visible magnetic resonance (MR) lesion(s) concordant with sextant of
                  biopsy-detected cancer(s)

               -  MRI within 6 months of treatment

          -  Karnofsky performance status of at least 70

          -  General health is suitable to undergo the planned minimally invasive procedures

          -  Risks, benefits, and alternatives discussed with informed consent given

        Exclusion Criteria:

          -  Previous treatment of prostate cancer with luteinizing hormone releasing hormone
             (LHRH) agonist/antagonist, chemotherapy, surgery, or radiation

          -  Presence of 3 or more visible lesions on MRI

          -  High suspicion of seminal vesicle invasion or lymph node metastases on MRI

          -  Unable to tolerate MRI (medical device, foreign body, claustrophobia, body habitus, or
             other)

          -  Renal insufficiency with estimated glomerular filtration rate (eGFR) &lt; 30 ml/min/body
             surface area (BSA) based on Modification in Diet Renal Disease equation; inability to
             safely receive gadolinium contrast for MRI

          -  History of prior pelvic surgery with surgical clips remaining in situ (e.g., bladder,
             bowel, internal pelvic organs) that compromise MRI image quality

          -  Other serious illnesses involving the cardiac, respiratory, central nervous system
             (CNS), or hepatic organ systems, which would preclude study completion or impede the
             determination of causality of any complications experienced during the conduct of this
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aytekin Oto</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Eggener, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <results_first_submitted>December 22, 2017</results_first_submitted>
  <results_first_submitted_qc>February 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2018</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (LITT)</title>
          <description>Patients undergo MR-guided laser ablation of prostate cancer
Visualase Thermal Therapy: MR guided laser ablation of prostate cancer
magnetic resonance imaging: Undergo MR-guided LITT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (LITT)</title>
          <description>Patients undergo MR-guided laser ablation of prostate cancer
Visualase Thermal Therapy: MR guided laser ablation of prostate cancer
magnetic resonance imaging: Undergo MR-guided LITT</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="47" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Undetectable Cancer on MRI-guided Biopsy of Ablation Zone Following Treatment</title>
        <description>The primary study end point was the number of patients with no cancer on MRI guided biopsy of the ablation zone at 3 months.</description>
        <time_frame>At 3 months after ablation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (LITT)</title>
            <description>Patients undergo MR-guided laser ablation of prostate cancer
Visualase Thermal Therapy: MR guided laser ablation of prostate cancer
magnetic resonance imaging: Undergo MR-guided LITT</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Undetectable Cancer on MRI-guided Biopsy of Ablation Zone Following Treatment</title>
          <description>The primary study end point was the number of patients with no cancer on MRI guided biopsy of the ablation zone at 3 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With Biopsy Cancer of the Treatment Zone</title>
        <description>A systematic 12-core biopsy was performed at 1 year and the number of patients with biopsy cancer was counted.</description>
        <time_frame>At 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (LITT)</title>
            <description>Patients undergo MR-guided laser ablation of prostate cancer
Visualase Thermal Therapy: MR guided laser ablation of prostate cancer
magnetic resonance imaging: Undergo MR-guided LITT</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With Biopsy Cancer of the Treatment Zone</title>
          <description>A systematic 12-core biopsy was performed at 1 year and the number of patients with biopsy cancer was counted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Number of Patients With Any Adverse Events Related to the Treatment</title>
        <description>Treatment-related toxicity measured by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0</description>
        <time_frame>1,3, and 12 month after treatment and up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (LITT)</title>
            <description>Patients undergo MR-guided laser ablation of prostate cancer
Visualase Thermal Therapy: MR guided laser ablation of prostate cancer
magnetic resonance imaging: Undergo MR-guided LITT</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Number of Patients With Any Adverse Events Related to the Treatment</title>
          <description>Treatment-related toxicity measured by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life in Terms of Urinary and Sexual Function in the Year Following Treatment Assessed Using the International Prostate Symptom Score (IPSS)</title>
        <description>International Prostate Symptom Score (IPSS) measures urinary symptoms and continence and it ranged 0 to 35. Lower values are considered better outcome.</description>
        <time_frame>At 1,3 and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (LITT)</title>
            <description>Patients undergo MR-guided laser ablation of prostate cancer
Visualase Thermal Therapy: MR guided laser ablation of prostate cancer
magnetic resonance imaging: Undergo MR-guided LITT</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life in Terms of Urinary and Sexual Function in the Year Following Treatment Assessed Using the International Prostate Symptom Score (IPSS)</title>
          <description>International Prostate Symptom Score (IPSS) measures urinary symptoms and continence and it ranged 0 to 35. Lower values are considered better outcome.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="1" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life in Terms of Urinary and Sexual Function in the Year Following Treatment Assessed Using Sexual Health Inventory in Men (SHIM)</title>
        <description>Sexual Health Inventory Score in Men (SHIM) measures sexual health and erectile function and it ranged 1 to 25. Lower values are considered better outcome.</description>
        <time_frame>At 1,3 and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (LITT)</title>
            <description>Patients undergo MR-guided laser ablation of prostate cancer
Visualase Thermal Therapy: MR guided laser ablation of prostate cancer
magnetic resonance imaging: Undergo MR-guided LITT</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life in Terms of Urinary and Sexual Function in the Year Following Treatment Assessed Using Sexual Health Inventory in Men (SHIM)</title>
          <description>Sexual Health Inventory Score in Men (SHIM) measures sexual health and erectile function and it ranged 1 to 25. Lower values are considered better outcome.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="1" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 3 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="1" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="3" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1,3 and 12 months after treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (LITT)</title>
          <description>Patients undergo MR-guided laser ablation of prostate cancer
Visualase Thermal Therapy: MR guided laser ablation of prostate cancer
magnetic resonance imaging: Undergo MR-guided LITT</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleeding per rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Aytekin Oto</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-834-7424</phone>
      <email>aoto@radiology.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

